Biotech News

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Beam Therapeutics (BEAM)Beam Therapeutics2026-02-24 12:01 ESTEarnings

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1

Beam Therapeutics

Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is...

Recent company news

BEAMBeam Therapeutics2026-08-04 11:00 EST

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

BEAMBeam Therapeutics2026-07-23 11:00 EST

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

BEAMBeam Therapeutics2026-06-18 11:00 EST

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

BEAMBeam Therapeutics2026-05-18 20:00 EST

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

BEAMBeam Therapeutics2026-05-13 11:00 EST

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

Stock data

Close: 27.25 USD
Market cap: 2.98B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States